Get the Stockscreener App
42.09
0.84%
0.35
After Hours:
42.09
Agios Pharmaceuticals Inc stock is traded at $42.09, with a volume of 324.19K.
It is up +0.84% in the last 24 hours and up +11.14% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$41.74
Open:
$41.92
24h Volume:
324.19K
Relative Volume:
0.44
Market Cap:
$2.45B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.7051
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+1.37%
1M Performance:
+11.14%
6M Performance:
+48.36%
1Y Performance:
-5.05%
1-Day Range:
$41.27
$42.11
1-Week Range:
$41.24
$43.69
52-Week Range:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
42.09 | 2.52B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Candlestick signals on Agios Pharmaceuticals Inc. stock todayGDP Growth & Real-Time Buy Zone Alerts - newser.com
Can Agios Pharmaceuticals Inc. stock reach $100 price target2025 Growth vs Value & AI Enhanced Trading Signals - newser.com
Can Agios Pharmaceuticals Inc. stock deliver sustainable ROEQuarterly Profit Review & Low Risk High Win Rate Stock Picks - newser.com
Is Agios Pharmaceuticals Inc. (8AP) stock considered safe havenM&A Rumor & Safe Entry Zone Identification - newser.com
How Agios Pharmaceuticals Inc. stock reacts to bond yieldsWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
Relative strength of Agios Pharmaceuticals Inc. in sector analysisMarket Movement Recap & Community Supported Trade Ideas - newser.com
Will Agios Pharmaceuticals Inc. see short term momentumMarket Activity Recap & Free Community Consensus Stock Picks - newser.com
Has Agios Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Short Interest & Weekly Stock Performance Updates - newser.com
Is Agios Pharmaceuticals Inc. stock supported by strong cash flowsDividend Hike & Smart Money Movement Alerts - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexesWatch List & Community Verified Swing Trade Signals - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock outperform Dow JonesIPO Watch & Free Technical Pattern Based Buy Signals - newser.com
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: 9.42% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Will Agios Pharmaceuticals Inc. outperform the market2025 Biggest Moves & Verified Entry Point Signals - newser.com
Why Agios Pharmaceuticals Inc. (8AP) stock gets analyst attentionPortfolio Value Summary & High Yield Stock Recommendations - newser.com
What analysts say about Agios Pharmaceuticals Inc stockStock Market Trends & Free Gain Edge With Data - earlytimes.in
Published on: 2025-10-20 16:50:40 - newser.com
Dividend Watch: Is Agios Pharmaceuticals Inc. (8AP) stock considered safe havenMarket Volume Summary & Weekly Watchlist of Top Performers - nchmf.gov.vn
H.C. Wainwright reiterates Buy rating on Agios Pharma stock amid positive EMA opinion - Investing.com Canada
Is Agios Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Movers & Daily Stock Trend Reports - newser.com
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia - BioSpace
Analyzing recovery setups for Agios Pharmaceuticals Inc. investorsWeekly Gains Summary & Safe Entry Point Identification - newser.com
Risk Check: Can Agios Pharmaceuticals Inc. stock rebound after recent weaknessTrade Analysis Summary & Expert Curated Trade Setup Alerts - nchmf.gov.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - WV News
Evaluating Agios Pharmaceuticals After 16% Rally and Positive Early Data on Mitapivat in Sickle Cell Disease - Yahoo Finance
Will Agios Pharmaceuticals Inc. stock maintain growth storyJuly 2025 Action & Weekly Setup with ROI Potential - nchmf.gov.vn
Will Agios Pharmaceuticals Inc. stock benefit from commodity prices2025 Earnings Surprises & Fast Gaining Stock Strategy Reports - nchmf.gov.vn
How Agios Pharmaceuticals Inc. stock performs during Fed tightening cyclesJuly 2025 Weekly Recap & Technical Pattern Based Signals - nchmf.gov.vn
Guidance Update: How Agios Pharmaceuticals Inc. stock performs during Fed tightening cyclesSwing Trade & Real-Time Stock Entry Alerts - nchmf.gov.vn
CHMP backs Agios’ PYRUKYND for thalassemia treatment in Europe By Investing.com - Investing.com Canada
Chart Watch: Can Agios Pharmaceuticals Inc. stock rebound after recent weaknessPortfolio Gains Report & Fast Momentum Entry Tips - nchmf.gov.vn
European regulators back Agios’ thalassemia treatment - Investing.com
CHMP backs Agios’ PYRUKYND for thalassemia treatment in Europe - Investing.com
Agios Pharmaceuticals Says EU Panel Gave Positive Opinion For Pyrukynd For Adults With Thalassemia - MarketScreener
Agios Pharmaceuticals (AGIO) Gains Positive CHMP Opinion for PYR - GuruFocus
Agios Pharmaceuticals Receives Positive CHMP Opinion for PYRUKYND® Indication in Thalassemia Treatment - Quiver Quantitative
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia - The Manila Times
European regulators back Agios’ thalassemia treatment By Investing.com - Investing.com UK
CHMP Issues Positive Opinion for PYRUKYND — Agios advances treatment for adults with thalassemia - Stock Titan
How Positive CHMP Opinion and European Deal for PYRUKYND May Impact Agios Pharmaceuticals (AGIO) Investors - Sahm
Why (AGIO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Agios Pharmaceuticals to Host Conference Call for Q3 2025 Financial Results and Business Highlights - Quiver Quantitative
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET - The Manila Times
What drives Agios Pharmaceuticals Inc stock priceGrowth vs. Value Investing & Free Wealth Planning Blueprints - earlytimes.in
Agios Q2 2025 slides: PYRUKYND sales jump 45% as thalassemia approval nears - Investing.com Australia
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):